Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 13, 2026

JPMorgan Chase & Co. Q4 Earnings Call Highlights

View original at finance.yahoo.com
JPMorgan Chase & Co. Q4 Earnings Call Highlights JPMorgan Chase & Co. logo Key Points JPMorgan reported Q4 net income of $13 billion and EPS of $4.63 on revenue of $46.8 billion (up 7% YoY) with ROTCE of 18%, and full‑year net income of $57.5 billion (EPS $20.18) excluding certain items…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Real estate is a very small number as an expense driver

    80% confidence
  • Consumers and small businesses remain resilient, with no current deterioration despite weak consumer sentiment

    80% confidence
  • The firm expects the 2026 card net charge-off rate to be approximately 3.4%, citing favorable delinquency trends and consumer resilience

    80% confidence
  • JPMorgan reported about $160 billion of NBFI exposure as of Q4, with loss history since 2018 including only one charge-off related to apparent fraud

    80% confidence
  • Wholesale credit trends show nothing concerning, with downgrades slightly exceeding upgrades and small parameter updates increasing assumed loss given default

    80% confidence
  • The Apple Card transaction is economically compelling and characterized as a win-win-win

    80% confidence
  • The elevated advanced RWA level is expected to be temporary and reduce to approximately $30 billion in the near term

    80% confidence
  • For 2026, NII ex-Markets is expected to be about $95 billion and total NII about $103 billion

    80% confidence
  • The quarter included the previously announced reserve build of $2.2 billion in CCB related to the forward purchase commitment of the Apple Card portfolio

    80% confidence
  • 2026 adjusted expense is expected to be about $105 billion

    80% confidence
  • Potential credit card APR caps would reduce access to credit broadly, especially for lower-FICO borrowers, and would be bad for JPMorgan

    80% confidence
  • JPMorgan reported Q4 net income of $13 billion and earnings per share of $4.63, with return on tangible common equity of 18%

    80% confidence
  • JPMorgan is not going to try to meet some expense target at the risk of being left behind competitively

    80% confidence
  • The Apple Card commitment contributed about $23 billion of standardized RWA and about $110 billion on an advanced basis

    80% confidence
  • The firm is making investments aligned with the greatest opportunities across businesses while the operating environment is becoming more competitive

    80% confidence
  • An undifferentiated APR cap would be very dramatic in its impact

    80% confidence
  • The firm's stablecoin advocacy is focused on preventing the creation of a parallel banking system that functions like banking without prudential safeguards

    80% confidence
  • Revenue totaled $46.8 billion, up 7% year over year, attributed to higher markets revenue, higher asset management fees, and auto lease income

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com